1. Summary

2. Objectives of The Study

3. Scope of the Report
3.1 Markets Covered
3.2 Years Considered for The Report
3.3 Currency

4. Market Research Methodology


5. Introduction
5.1 Overview
5.2 Natural Huperzine A and Synthetic Huperzine A
5.3 Value Chain
5.4 Mechanisms of Action
5.5 Product Form (Tablet, Capsule, Injection, etc.)


6. Product Pipeline
6.1 Wagelan/???
6.2 Yinuo/??
6.3 Shuangyiping/???
6.4 DEBIO 9902
6.5 MemorAll?
6.6 XEL 001HP


7. Rule, Regulation and Policy
7.1 Regulation and Policy in China
7.2 Regulation and Policy in Other Countries


8. Market Landscape
8.1 Market Size and Forecast
8.2 Market by Company


9. Alzheimer’s Disease
9.1 The Basics of Alzheimer’s Disease
9.2 Stages of Alzheimer’s Disease
9.3 Therapies for Alzheimer’s Disease
9.4 Huperzine A in the Treatment of Alzheimer’s Disease


10. Huperzine A Market by Region
10.1 Huperzine A Market in North America
10.2 Huperzine A Market in Europe
10.3 Huperzine A Market in China


11. Drivers & Challenges
11.1 Market Growth Drivers
11.2 Market Challenges
11.3 Market Trends


12. Patents Analysis
12.1 Global Huperzine A Patents Analysis
12.2 China’s Huperzine A Patents Analysis


13. Key Vendor Analysis
13.1 Debiopharm Group
13.2 Cisen Pharmaceutical Co., Ltd.
13.3 Beijing Hwells Pharmaceutical Co., Ltd.
13.4 XYMOGEN, Inc.
13.5 Xel Pharmaceuticals, Inc.
13.6 Hainan Lingkang Pharmaceutical Co., Ltd.
13.7 Simcere Pharmaceutical Group
13.8 Henan Taloph Pharmaceutical Stock Co.
13.9 Ningbo Liwah Pharmaceutical Co., Ltd.
13.10 Ningbo Green-Health Pharma-ceutical Co., Ltd
13.11 Shanghai Fudan Forward Pharmaceutical Co., Ltd.
13.12 Shenzhen Zhonglian Pharmaceutical Co., Ltd.
13.13 Wanbang Pharmaceutical Group Co., Ltd.
13.14 Zhejiang Judu Pharmaceutical Group Co.,Ltd.
13.15 Zhejiang Zhenyuan Pharmaceutical Co., Ltd.
13.16 Yaoyou Chongqing Pharmaceutical Co., Ltd.

14. Attachment

DISCLAIMER
ABOUT GEN CONSULTING COMPANY